<div id="readability-page-1"><p>Morgan Stanley analyst Sarita Kapila maintained a Buy rating on UCB SA today and set a price target of €260.00.</p><h3>TipRanks Cyber Monday Sale</h3><ul><li> Claim 60% off TipRanks Premium  for data-backed insights and research tools you need to invest with confidence.  </li><li>  Subscribe to TipRanks' Smart Investor Picks  and see our data in action through our high-performing model portfolio - <u> now also 60% off </u></li></ul> <p>According to TipRanks, Kapila is an analyst with an average return of <span>-1.6%</span> and a 52.38% success rate. Kapila covers the Healthcare sector, focusing on stocks such as GlaxoSmithKline, UCB SA, and AstraZeneca.</p> <p>UCB SA has an analyst consensus of Moderate Buy, with a price target consensus of €263.22.</p></div>

UCBJY

<p>Morgan Stanley analyst Sarita Kapila maintains a Buy rating for UCB SA, setting a price target of €260.00. Kapila, who covers the Healthcare sector, has an average return of -1.6% and a 52.38% success rate. UCB SA has a Moderate Buy consensus with a price target of €263.22.</p>

Morgan Stanley Sticks to Its Buy Rating for UCB SA (0NZT)